Regencell Bioscience Holdings Limited (RGC) Fair Value 2026

RGC · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-28, Regencell Bioscience Holdings Limited (RGC) trades at $5.50. QOC: 4.8/10. Value Trap Risk: 43/100 (WARN). 0/13 models active.

Key Facts

Ticker
RGC
Price
$5.50
Quality Score
4.8/10
Value Trap Risk
43/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give RGC?

0 Intrinsic Value Models vs. Current Price ($5.50)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Regencell Bioscience Holdings Limited (RGC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Regencell Bioscience Holdings Limited currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About RGC?

0 of 13 models are currently active for RGC. See which stocks rank higher →

How Does RGC Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, RGC ranks #82 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Regencell Bioscience Holdings Limited's positioning within the Drug Manufacturers - Specialty & Generic segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.

Is RGC a Value Trap?

CirclFi's Value Trap algorithm assigns RGC a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Regencell Bioscience Holdings Limited. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Regencell Bioscience Holdings Limited scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RGC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Regencell Bioscience Holdings Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

HYEXHealthy Extracts Inc.QOC 4.9OWPCOne World Products, Inc.QOC 4.7APUSApimeds Pharmaceuticals US, Inc.QOC 5.0BTAIBioXcel Therapeutics, Inc.QOC 4.7CANNTrees CorporationQOC 5.1GELSGelteq LimitedQOC 4.7UPCUniverse Pharmaceuticals INCQOC 1.8ELANElanco Animal Health IncorporatedQOC 7.2INISRadnostix, Inc.QOC 6.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: HYEX · OWPC · APUS · BTAI · CANN · GELS · UPC · ELAN · INIS · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to RGC?

7 companies across all industries closest to RGC’s Quality of Company score of 4.8/10.

ATOSAtossa Therapeutics, Inc.QOC 4.8LONALeonaBio, Inc.QOC 4.8ALURAllurion Technologies Inc.QOC 4.8XXITwenty One Capital, Inc.QOC 4.8MLYSMineralys Therapeutics, Inc.QOC 4.8SRCOSparta Commercial Services, Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ATOS · LONA · ALUR · XXI · MLYS · SRCO · NVDA

Where Does RGC Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

RGC is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Regencell Bioscience Holdings Limited’s Valuation?

What is Regencell Bioscience Holdings Limited's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Regencell Bioscience Holdings Limited (RGC). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RGC overvalued or undervalued right now?

At $5.50, 0 of 0 active models suggest RGC may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Regencell Bioscience Holdings Limited's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 4.8 mean for RGC?

Regencell Bioscience Holdings Limited's QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RGC?

CirclFi analyzes RGC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is RGC a value trap in 2026?

Regencell Bioscience Holdings Limited's Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Regencell Bioscience Holdings Limited (RGC) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/RGC/ · Methodology
Primary sources for this RGC valuation

Market data for RGC as of ; valuations recomputed .